Gamma Knife Radiosurgery For Cerebellar HemangioblastomasKeywords: hemangioblastoma, gamma knife, cerebellum, outcome, von Hippel-Lindau diseaseInteractive Manuscript
Ask Questions of this Manuscript:
What is the background behind your study?
What is the purpose of your study?
The objective of this study was to assess the role of radiosurgery (RS) in the management of primary or recurrent cerebellar hemangioblastomas.
Describe your patient group.
Retrospective analysis of 10 patients out of 11 consecutive patients with cerebellar hemangioblastomas (21 lesions) treated with RS between 1999 and 2008. RS was delivered with Gamma Knife for primary (16 lesions) or recurrent (5 lesions) hemangioblastomas. Seven patients had von Hippel-Lindau disease-associated hemangioblastomas (15 lesions) and 3 had sporadic hemangioblastomas (6 lesions).
Describe what you did.
The median dose was 15 Gy (13 – 24 Gy) and the median target volume was 0,8 mL (0,01 - 11,5 mL).
Describe your main findings.
The median follow-up was 36,5 months (6 -114 months). Tumor growth was controlled in 85,7% (8 in 21) of the cases. One patient died from disease progression. The progression-free survival after RS at 1 and 3 years was 100% and 89%, respectively. No complication such as radiation-induced peritumoral edema or radiation necrosis occurred.
Describe the main limitation of this study.
This is a retrospective study.
Describe your main conclusion.
These early results show that RS provides a high local control rate of cerebellar hemangioblastomas.
Describe the importance of your findings and how they can be used by others.
Also RS is associated with a low risk of adverse radiation effects and is an attractive alternative to multiple surgical procedures for patients with von Hippel-Lindau disease.
The objective of this study was to assess the role of radiosurgery (RS) in the management of primary or recurrent cerebellar hemangioblastomas.
Retrospective analysis of 10 patients out of 11 consecutive patients with cerebellar hemangioblastomas (21 lesions) treated with RS between 1999 and 2008. RS was delivered with Gamma Knife for primary (16 lesions) or recurrent (5 lesions) hemangioblastomas. Seven patients had von Hippel-Lindau disease-associated hemangioblastomas (15 lesions) and 3 had sporadic hemangioblastomas (6 lesions).
The median dose was 15 Gy (13 – 24 Gy) and the median target volume was 0,8 mL (0,01 - 11,5 mL).
The median follow-up was 36,5 months (6 -114 months). Tumor growth was controlled in 85,7% (8 in 21) of the cases. One patient died from disease progression. The progression-free survival after RS at 1 and 3 years was 100% and 89%, respectively. No complication such as radiation-induced peritumoral edema or radiation necrosis occurred.
This is a retrospective study.
These early results show that RS provides a high local control rate of cerebellar hemangioblastomas.
Also RS is associated with a low risk of adverse radiation effects and is an attractive alternative to multiple surgical procedures for patients with von Hippel-Lindau disease.
Project Roles:
